Quantum BioPharma Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.58next fiscal year
Monitoring Framework
Key Performance Indicators
Combined Cash, Cash Equivalents, and Digital Assets Quarterly9.8MTarget: Sufficient working capital to fund operations through July 2027
Operating Cash Outflow (Quarterly) Quarterly1.7MTarget: Maintain disciplined cost management and low cash burn
Unbuzzd Wellness Inc. Ownership Stake Quarterly0.2Target: Maximize equity value and support nationwide commercialization
Watch Items
- FDA Clinical Hold Resolution for Lucid-MS Phase 2 TrialTrigger: Submission of formal response package and subsequent FDA feedbackAction: Collaborate with clinical advisors and development partners to address FDA comments and lift the clinical hold.
- Unbuzzd Commercialization and Royalty Revenue StreamTrigger: Initial commercial sales of unbuzzd™ beverage under new CEO Richard BuzbuzianAction: Monitor nationwide rollout in South Florida and Texas to track progress toward the 7% royalty stream (up to $250M).
- CIBC and RBC Market Manipulation Lawsuit ($700M Claim)Trigger: Court proceedings following the denial of the defendants' joint motion to dismissAction: Track legal developments and potential monetization or settlement opportunities related to the litigation-linked CVRs.
Research as of 20 Jun 2026